Bicycle therapies offer continued hope for advanced tumors
NCT ID NCT07681674
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while researchers monitor long-term safety. The goal is to allow ongoing treatment for those who are tolerating it well and whose disease has not progressed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zelenectide pevedotin, BT7480, Nuzefatide pevedotin
- What this could lead to
- If successful, this could provide a way for people with advanced solid tumors to keep receiving a promising experimental treatment that is helping them.
- What could go wrong
- This is a small, early-phase study focused on safety, not on proving the treatment works. The drugs are still experimental and may have unknown side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection shrink Hard-to-Treat tumors?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Dual-Action antibody outsmart resistant tumors?
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?